{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:51:37Z","timestamp":1792036297534,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"crossref","award":["SPF2012\/005"],"award-info":[{"award-number":["SPF2012\/005"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12035-018-1393-1","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T17:05:40Z","timestamp":1539795940000},"page":"4464-4478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease"],"prefix":"10.1007","volume":"56","author":[{"given":"Marta","family":"Garcia-Miralles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Amirah Binte Mohammad","family":"Yusof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola I.","family":"Radulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harwin","family":"Sidik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Juin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Zach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-0976","authenticated-orcid":false,"given":"Mahmoud A.","family":"Pouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"publisher","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, et al. (2015) Huntington disease. Nat Rev Dis Primers 15005. doi: \n                    https:\/\/doi.org\/10.1038\/nrdp.2015.5","DOI":"10.1038\/nrdp.2015.5"},{"key":"1393_CR2","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007) Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 130:1759\u20131766. \n                    https:\/\/doi.org\/10.1093\/brain\/awm044","journal-title":"Brain"},{"key":"1393_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.coph.2015.09.008","volume":"26","author":"R Andre","year":"2015","unstructured":"Andre R, Carty L, Tabrizi SJ (2015) Disruption of immune cell function by mutant huntingtin in Huntington\u2019s disease pathogenesis. Curr Opin Pharmacol 26:33\u201338. \n                    https:\/\/doi.org\/10.1016\/j.coph.2015.09.008","journal-title":"Curr Opin Pharmacol"},{"key":"1393_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti A, Glass CK (2015) The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol 36:364\u2013373. \n                    https:\/\/doi.org\/10.1016\/j.it.2015.04.007","journal-title":"Trends Immunol"},{"key":"1393_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41380-018-0021-9","volume":"16","author":"HL Denis","year":"2018","unstructured":"Denis HL, Lauruol F, Cicchetti F (2018) Are immunotherapies for Huntington\u2019s disease a realistic option? Mol Psychiatry 16:889. \n                    https:\/\/doi.org\/10.1038\/s41380-018-0021-9","journal-title":"Mol Psychiatry"},{"key":"1393_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP et al (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161\u2013172","journal-title":"J Neuropathol Exp Neurol"},{"key":"1393_CR7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","volume":"66","author":"N Pavese","year":"2006","unstructured":"Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638\u20131643. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000222734.56412.17","journal-title":"Neurology"},{"key":"1393_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 205:1869\u20131877. \n                    https:\/\/doi.org\/10.1084\/jem.20080178","journal-title":"J Exp Med"},{"key":"1393_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA et al (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum Brain Mapp 32:258\u2013270. \n                    https:\/\/doi.org\/10.1002\/hbm.21008","journal-title":"Hum Brain Mapp"},{"key":"1393_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","volume":"83","author":"M Politis","year":"2015","unstructured":"Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE et al (2015) Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers. Neurobiol Dis 83:115\u2013121. \n                    https:\/\/doi.org\/10.1016\/j.nbd.2015.08.011","journal-title":"Neurobiol Dis"},{"key":"1393_CR11","doi-asserted-by":"publisher","first-page":"RRN1231","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, Bj\u00f6rkqvist M (2011) Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr 3:RRN1231. \n                    https:\/\/doi.org\/10.1371\/currents.RRN1231","journal-title":"PLoS Curr"},{"key":"1393_CR12","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/JCI64565","volume":"122","author":"A Weiss","year":"2012","unstructured":"Weiss A, Tr\u00e4ger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N et al (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Invest 122:3731\u20133736. \n                    https:\/\/doi.org\/10.1172\/JCI64565","journal-title":"J Clin Invest"},{"key":"1393_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2014.04.002","volume":"262PA","author":"M Varrin-Doyer","year":"2014","unstructured":"Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U (2014) Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol 262PA:66\u201371. \n                    https:\/\/doi.org\/10.1016\/j.expneurol.2014.04.002","journal-title":"Exp Neurol"},{"key":"1393_CR14","doi-asserted-by":"publisher","first-page":"E6145","DOI":"10.1073\/pnas.1607843113","volume":"113","author":"J Kaye","year":"2016","unstructured":"Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS et al (2016) Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. PNAS 113:E6145\u2013E6152. \n                    https:\/\/doi.org\/10.1073\/pnas.1607843113","journal-title":"PNAS"},{"key":"1393_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2012.06.005","volume":"251","author":"R Aharoni","year":"2012","unstructured":"Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R (2012) Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 251:14\u201324. \n                    https:\/\/doi.org\/10.1016\/j.jneuroim.2012.06.005","journal-title":"J Neuroimmunol"},{"key":"1393_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajpath.2011.09.037","volume":"180","author":"J Th\u00f6ne","year":"2012","unstructured":"Th\u00f6ne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G et al (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180:267\u2013274. \n                    https:\/\/doi.org\/10.1016\/j.ajpath.2011.09.037","journal-title":"Am J Pathol"},{"key":"1393_CR17","doi-asserted-by":"publisher","first-page":"31652","DOI":"10.1038\/srep31652","volume":"6","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S et al (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 6:31652. \n                    https:\/\/doi.org\/10.1038\/srep31652","journal-title":"Sci Rep"},{"key":"1393_CR18","doi-asserted-by":"publisher","unstructured":"Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X et al (2017) Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight 2. \n                    https:\/\/doi.org\/10.1172\/jci.insight.95665","DOI":"10.1172\/jci.insight.95665"},{"key":"1393_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrn2652","volume":"10","author":"SP Brooks","year":"2009","unstructured":"Brooks SP, Dunnett SB (2009) Tests to assess motor phenotype in mice: a user\u2019s guide. Nat Rev Neurosci 10:519\u2013529. \n                    https:\/\/doi.org\/10.1038\/nrn2652","journal-title":"Nat Rev Neurosci"},{"key":"1393_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/brain\/awp006","volume":"132","author":"MA Pouladi","year":"2009","unstructured":"Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, Hayden MR (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132:919\u2013932. \n                    https:\/\/doi.org\/10.1093\/brain\/awp006","journal-title":"Brain"},{"key":"1393_CR21","unstructured":"Paxinos G, Franklin KB (2012) Paxinos and franklin's the mouse brain in stereotaxic coordinates. Academic Press"},{"issue":"5","key":"1393_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/brain\/awp042","volume":"132","author":"Daniel Barazany","year":"2009","unstructured":"Barazany D, Basser PJ, Assaf Y (2009) In vivo measurement of axon diameter distribution in the corpus callosum of rat brain. Brain 132(5):1210\u20131220","journal-title":"Brain"},{"key":"1393_CR23","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/hmg\/dds037","volume":"21","author":"MA Pouladi","year":"2012","unstructured":"Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W et al (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 21:2219\u20132232. \n                    https:\/\/doi.org\/10.1093\/hmg\/dds037","journal-title":"Hum Mol Genet"},{"key":"1393_CR24","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","volume":"14","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:3823\u20133835. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddi407","journal-title":"Hum Mol Genet"},{"key":"1393_CR25","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","volume":"25","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR et al (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington\u2019s disease. J Neurosci 25:4169\u20134180. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.0590-05.2005","journal-title":"J Neurosci"},{"key":"1393_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.nbd.2011.03.018","volume":"43","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR (2011) Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol Dis 43:257\u2013265. \n                    https:\/\/doi.org\/10.1016\/j.nbd.2011.03.018","journal-title":"Neurobiol Dis"},{"key":"1393_CR27","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1093\/hmg\/ddw122","volume":"25","author":"RTY Teo","year":"2016","unstructured":"Teo RTY, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L et al (2016) Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Hum Mol Genet 25:2621\u20132632. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddw122","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1393_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","volume":"124","author":"Wolfgang Br\u00fcck","year":"2012","unstructured":"Br\u00fcck W, Pf\u00f6rtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V et al. (2012) Reduced astrocytic NF-\u03baB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathologica 124(3):411\u2013424. \n                    https:\/\/doi.org\/10.1007\/s00401-012-1009-1","journal-title":"Acta Neuropathologica"},{"key":"1393_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling D, Huang S-Y, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863\u2013874. \n                    https:\/\/doi.org\/10.1016\/j.cell.2011.05.020","journal-title":"Cell"},{"key":"1393_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.expneurol.2016.06.008","volume":"283","author":"DE Ehrnhoefer","year":"2016","unstructured":"Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR (2016) Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Exp Neurol 283:121\u2013128. \n                    https:\/\/doi.org\/10.1016\/j.expneurol.2016.06.008","journal-title":"Exp Neurol"},{"key":"1393_CR31","doi-asserted-by":"publisher","first-page":"9544","DOI":"10.1523\/JNEUROSCI.1291-11.2011","volume":"31","author":"Z Xiang","year":"2011","unstructured":"Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q et al (2011) Peroxisome-proliferator-activated receptor gamma coactivator 1 \u03b1 contributes to dysmyelination in experimental models of Huntington\u2019s disease. J Neurosci 31:9544\u20139553. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.1291-11.2011","journal-title":"J Neurosci"},{"key":"1393_CR32","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1093\/hmg\/ddv016","volume":"24","author":"J Jin","year":"2015","unstructured":"Jin J, Peng Q, Hou Z, Jiang M, Wang X, Langseth AJ, Tao M, Barker PB et al (2015) Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington\u2019s disease. Hum Mol Genet 24:2508\u20132527. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddv016","journal-title":"Hum Mol Genet"},{"key":"1393_CR33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1152\/physrev.2001.81.2.871","volume":"81","author":"N Baumann","year":"2001","unstructured":"Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871\u2013927","journal-title":"Physiol Rev"},{"key":"1393_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12035-009-8071-2","volume":"40","author":"O Jahn","year":"2009","unstructured":"Jahn O, Tenzer S, Werner HB (2009) Myelin proteomics: molecular anatomy of an insulating sheath. Mol Neurobiol 40:55\u201372. \n                    https:\/\/doi.org\/10.1007\/s12035-009-8071-2","journal-title":"Mol Neurobiol"},{"key":"1393_CR35","doi-asserted-by":"publisher","first-page":"E1319","DOI":"10.1073\/pnas.1715999115","volume":"115","author":"G Shackleford","year":"2018","unstructured":"Shackleford G, Sampathkumar NK, Hichor M et al (2018) Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis. PNAS 115:E1319\u2013E1328. \n                    https:\/\/doi.org\/10.1073\/pnas.1715999115","journal-title":"PNAS"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1393-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:05:30Z","timestamp":1571252730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1393-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1393-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"5 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"N.Z., H.B. and M.R.H. are employees of Teva Pharmaceuticals, and contributed to the study design and revision of the manuscript. Teva Pharmaceuticals played no role in the treatment or testing of animals, or the collection, analysis and interpretation of the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}